It is a product of URIT. On the basis of the original urine routine analysis workflow, US-3000 series has added urine-specific protein module and urine biochemistry detection module to realize one-stop detection of urine physics, dry chemistry, formed element, specific protein, and biochemical quantification. On the basis of all-in-one machine, US-1680 series adds online functions to meet the needs of different markets.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026.

Produced by AVE, it has a high degree of automation, and the front end is equipped with automatic sample delivery device.

Eyonis Inc., a Median Technologies company focused on applying artificial intelligence to the early detection and diagnosis of cancer, today announced that Median Technologies has entered into a strategic commercial agreement with Olea Medical, a Canon Medical Systems company, that will expand U.S. access to eyonis® LCS Lung Cancer Screening. The broader agreement also covers Europe and other markets that may be mutually agreed upon over time.

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The Board of Directors of Diasorin S.p.A. (FTSE MIB: DIA) meeting today, examined and approved the Group’s Consolidated Financial Statements at June 30, 2026.

Siemens Healthineers AG today announces its results for the third quarter of fiscal year 2026 ended June 30, 2026.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2026.

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026.